Innovus launches low-cost nasal spray allergy relief in FlutiCare
Earlier this month Innovus Pharmaceuticals launched FlutiCare OTC in the U.S., making it the third branded fluticasone propionate nasal spray on the market. Innovus, based in San Diego, secured distribution through more than 10,000 independent pharmacies through AmerisourceBergen and McKesson and Walmart online.
As a second phase of its launch, Innovus Pharma will launch FlutiCare to large retail stores.
FlutiCare will be available OTC with the same prescription strength and same delivery method as Flonase and ClariSpray. The company currently believes that FlutiCare will be the most affordable fluticasone propionate nasal spray on the market and is now available in one dose, a 30 Day (120 Sprays) treatment. Innovus is also offering a monthly autoship plan.
“We are very excited to launch FlutiCare OTC and provide all patients with allergy relief,” stated Bassam Damaj, president and CEO Innovus Pharma. “FlutiCare traces its roots as the most prescribed Rx 24-hour nasal allergy spray API and form in the U.S. over the past 7 years by a factor of over 10 to 1.”
FlutiCare becomes the company’s second available allergy relief product along with AllerVarx, a patented dietary supplement formulated to provide relief during the allergy season, already on the market.
In addition, the company, pending FDA’s guidance, plans to move forward with a fluticasone kit for nasal allergy containing FlutiCare and its upcoming saline nasal spray NasaVa.